Recent

% | $
Quotes you view appear here for quick access.

Isis Pharmaceuticals, Inc. Message Board

  • zba5552003 zba5552003 Mar 12, 2013 5:35 AM Flag

    News overdue!

    ISIS Pharmaceuticals, Inc. (ISIS) Update On Its Metabolic Franchise Conference Call December 7, 2012
    Isis-FGFR4: three month ago
    Stan Crookje "It is a very complicated study because we are looking at normal volunteers and trying to measure a variety of, particularly, FGF19, which is a difficult to measure substance. So the study has actually completed but the data analysis is taking quite a long time. Just to get all the information procedures, specialized assays. So it will be a little while. I could have just said, it will be a little while.

    ISIS-CRPRx JPM Conference/09. January 2013
    Endotoxin Challenge Study in ~30 Healthy Volunteers (Completed)
    Study designed to demonstrate that ISIS-CRPRx can blunt acute severe
    increases in CRP
    Exploring other key inflammatory mediators such as TNF-α, IL-1β, IL-6
    and complement
    Data planned for 1H 2013

    ISIS-APOCIIIRx
    Severely Elevated Triglyceride Study, ~100 Patients with Triglycerides between 440-2000
    mg/dL (Ongoing) 09.01.2013
    Study designed to demonstrate that ISIS-APOCIIIRx can decrease triglycerides and apoC-III in
    patients with severely elevated triglycerides
    Doses: 100, 200, or 300 mg/wk
    Data planned for mid 2013

    Isis Initiates Phase 2 Study of ISIS-APOCIIIRx in Patients with Hypertriglyceridemia/ 04. May 2012

    8 weeks: Screening & Diet Run-in
    13 weeks: Treatment Period
    12 weeks: Post-Treatment #$%$ Period
    = 8 month --- completed about end of January 2013

 
ISIS
50.18-1.36(-2.64%)Aug 31 4:00 PMEDT